Literature DB >> 30445207

Molecular epidemiology and genetic characterisation of carbapenem-resistant Acinetobacter baumannii isolates from Guangdong Province, South China.

Lili Jiang1, Youcai Liang2, Wei Yao3, Juntao Ai4, Xin Wang1, Zuguo Zhao5.   

Abstract

OBJECTIVES: Carbapenem-resistant Acinetobacter baumannii (CRAB) has become a worldwide issue. This study aimed to characterise the epidemiology and genetic relationships of A. baumannii isolates in Guangdong Province, China.
METHODS: CRAB isolates were collected from five municipal hospitals from June-December 2017. The 16S-23S rRNA intergenic spacer region was used for confirmation of strain identity. Antimicrobial susceptibility testing and the CarbAcineto NP test were performed to analyse the resistance spectrum and carbapenemase production of the isolates. PCR-based assays were used to detect β-lactamase genes and related mobile genetic elements. Genetic diversity among the isolates was analysed by enterobacterial repetitive intergenic consensus (ERIC)-PCR, multilocus sequence typing (MLST) and multiplex PCR.
RESULTS: A total of 122 isolates were confirmed as A. baumannii; all were resistant to the tested antibiotics except for tigecycline and colistin. The CarbAcineto NP test showed that 93.4% of the isolates produced a carbapenemase. blaOXA-23-like and extended-spectrum β-lactamase-encoding genes were found by PCR in 94.3% and 91.8% of the isolates, respectively. Furthermore, the genetic environment of blaOXA-23-like was mainly associated with transposons Tn2008 (46.1%), Tn2006 (27.0%) and Tn2009 (20.9%). MLST identified six existing sequence types (STs) and three novel STs, of which ST195 (35.7%) and ST208 (32.1%) were the most common, belonging to clonal group 92 and European clone II.
CONCLUSION: This study suggests that co-production of β-lactamases was the major resistance mechanism of CRAB isolates. Dissemination of blaOXA-23-like may be facilitated by transposable elements. ST195 and ST208 were the predominant epidemic types of A. baumannii in Guangdong Province.
Copyright © 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Carbapenem resistance; Mobile genetic element; Molecular typing; Oxacillinase

Mesh:

Substances:

Year:  2018        PMID: 30445207     DOI: 10.1016/j.jgar.2018.11.002

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  5 in total

1.  The Spread of Insertion Sequences Element and Transposons in Carbapenem Resistant Acinetobacter baumannii in a Hospital Setting in Southwestern Iran.

Authors:  Zahra Hashemizadeh; Gholamreza Hatam; Javad Fathi; Fatemeh Aminazadeh; Hossein Hosseini-Nave; Mahtab Hadadi; Nafiseh Hosseinzadeh Shakib; Sodeh Kholdi; Abdollah Bazargani
Journal:  Infect Chemother       Date:  2022-06-02

Review 2.  The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.

Authors:  Dalal Hammoudi Halat; Carole Ayoub Moubareck
Journal:  Antibiotics (Basel)       Date:  2020-04-16

3.  Origin, Phylogeny, and Transmission of the Epidemic Clone ST208 of Carbapenem-Resistant Acinetobacter baumannii on a Global Scale.

Authors:  Yue Gao; Henan Li; Hongbin Chen; Jiangang Zhang; Ruobing Wang; Zhiren Wang; Hui Wang
Journal:  Microbiol Spectr       Date:  2022-05-31

4.  Characterization of carbapenem-resistant hypervirulent Acinetobacter baumannii strains isolated from hospitalized patients in the mid-south region of China.

Authors:  Jun Li; Ting Yu; Yi Luo; Jing-Yi Peng; Yu-Jia Li; Xiao-Yan Tao; Yong-Mei Hu; Hai-Chen Wang; Ming-Xiang Zou
Journal:  BMC Microbiol       Date:  2020-09-14       Impact factor: 3.605

5.  Synergistic Antibacterial Activity of Combined Antimicrobials and the Clinical Outcome of Patients With Carbapenemase-Producing Acinetobacter baumannii Infection.

Authors:  Junyan Qu; Rujia Yu; Qujue Wang; Chunlu Feng; Xiaoju Lv
Journal:  Front Microbiol       Date:  2020-10-15       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.